A Health Ministry panel postponed a decision on Wednesday on whether to grant Shionogi’s COVID-19 pill emergency approval, citing the need for further discussion.
The oral drug, which is the first domestically developed COVID-19 treatment and is intended for use in patients with mild to moderate symptoms, had been evaluated by the panel after the Osaka-based pharmaceutical company applied for approval. under the emergency authorization system. created in May.
In an age of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us tell the story well.